Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Somavaratan Long-Term Safety in Pediatric GHD
NCT02068521Phase 3Terminated
- Sponsor
- Versartis, Inc.
- Start
- Mar 2014
- Primary completion
- Nov 2017
- Modality
- Fc-Fusion Proteins
01
Overview
Phase 3, open-label trial of somavaratan in growth hormone deficiency (GHD) (2 arms), sponsored by Versartis, Inc. Primary endpoint: Safety up to 4 years. Started Mar 2014; status: terminated.
02
Drugs
somavaratan
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on NCT02068521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02068521.